Navigation Links
Vandetanib in thyroid cancer: No proof of added benefit
Date:11/9/2012

Vandetanib (trade name Caprelsa) has been approved in Germany since February 2012 for adult patients suffering from a particular form of aggressive thyroid cancer. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit of the drug pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG). According to the findings, there is no proof of added benefit, because no data on patient-relevant outcomes for those patients for whom the drug is approved were presented by the drug manufacturer in its dossier. In view of these deficiencies, IQWiG considered itself compelled to declare the contents of the dossier as "incomplete".

"Best supportive care" as the appropriate comparator therapy

As specified by the Federal Joint Committee (G-BA), vandetanib should be compared with "best supportive care". This means the best possible supportive therapy, optimized for the individual patient for alleviation of symptoms and improvement in the quality of life.

The only study relevant for this benefit assessment compared the administration of vandetanib in combination with "best supportive care" with a treatment consisting of "best supportive care" alone.

Study population differs from approval population

Vandetanib is approved for patients with an "aggressive and symptomatic" medullary thyroid cancer (MTC) in whom surgery is no longer possible, the cancer is already very large or from which secondaries (metastases) have already formed in other regions of the body. The European regulatory authority - the European Medicines Agency (EMA) - had restricted the therapeutic indication in such a way in order to produce an overall positive benefit-risk balance. This is because treatment with vandetanib also involves major risks and can, for example, lead to severe heart rhythm disturbances.

However, in the study presented by the manufacturer, patients in whom the course of the disease was not "aggressive and symptomatic" were also enrolled. This applied to a total of about 44% of the study participants. This means that the study population - in contrast to the statements made by the manufacturer - was much wider than just the approval population. A benefit assessment pursuant to AMNOG should, however, only be undertaken for patients for whom the drug is actually approved. But the analysis of the study presented by the manufacturer did not allow for this.

Separate analysis would have been possible

The pharmaceutical company did not provide a separate analysis of the data with regard to patient-relevant outcomes (mortality, morbidity, quality of life) for patients treated in accordance with the approval status. However, comments of the EMA from the approval process prove that this group of patients is clearly distinguishable within the study and therefore the company could have presented a separate analysis for the benefit assessment.

The incompleteness of the dossier does not allow a reliable assessment of the new drug. An added benefit of vandetanib compared with "best supportive care" is therefore not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessment conducted by the G-BA. After publication of the manufacturer's dossier and its assessment by IQWiG, the G-BA initiates a formal commenting procedure, which provides further information and can result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>
Contact: Dr. Anna-Sabine Ernst
presse@iqwig.de
0049-221-356-856
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Thyroid Condition Linked to Heart Problems: Study
2. Lower-Dose Radioiodine Effective Against Thyroid Cancer
3. Staging and risk stratification of thyroid cancer improved with SPECT/CT
4. Obese More Likely to Be Diagnosed With Advanced Thyroid Cancer
5. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
6. Hyperthyroidism linked to increased risk of hospitalization for heart and blood-vessel disease
7. Gene expression test identifies low-risk thyroid nodules
8. Detecting thyroid disease by computer
9. Experts issue recommendations for treating thyroid dysfunction during and after pregnancy
10. Drug May Aid People With Advanced Thyroid Cancer
11. Thyroid Treatment Guidelines for Pregnant Women Revised
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, ... freedom to people who need help getting around. For some, advancing age has led ... of rehabilitation after an illness or accident. There is a wide variety of scooters, ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... Austin, TX (PRWEB) , ... December 05, 2016 ... ... Center for Facial Plastic Surgery, is excited to announce the arrival of the ... hybrid fractional laser, with the ability to use tunable non-ablative and ablative wavelengths ...
(Date:12/5/2016)... ... 05, 2016 , ... SyncDog, Inc., the leading ISV for ... leading online tech news platform connecting technology innovators with news, experience, and knowledge ... state of enterprise mobility security today, and how the SyncDog SentinelSecure™ product line ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... with leading global lifestyle design firm kathy ireland® Worldwide for five additional years, ... Worldwide entered into an exclusive licensing agreement three years ago to design and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... Sanovas, Inc., a life science asset holding company ... wholly owned subsidiary, Intubation Science, Inc., and its LightSpeed Intubation ... http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... Sanovas, Inc. ... There are over 40 million Endotracheal Intubations performed annually ...
(Date:12/5/2016)... Health and Gateway Health proudly announce a dynamic collaboration that ... plan members with specific high risk needs. In ... group of consumers, Wellbridge combines technology and population expertise with ... members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... Dec. 5, 2016  Recently Zymo Research announced ... predictor, known as Horvath,s Clock. Based on this ... analysis service to academic and biopharma scientific researchers ... sample, other than sperm. The service ... biological age versus chronological age following drug treatments ...
Breaking Medicine Technology: